Arecor’s objective is to develop stable advanced formulations through the application of Arestat™ that are commercially relevant for their industrial partners. Arecor therefore seeks partners with therapeutic or diagnostic candidates that are : (i) difficult to stabilize through conventional formulation methods or (ii) which could benefit from a change in presentation such as a ‘lyophilized powder in vials’ to ‘ready-to-use liquid in pre-filled syringes’ or (iii) an aqueous solution with instructions to ‘store refrigerated at 2-8°C’ being available as ‘store at room temperature’.
Our aim is to address the stability issues which may seem insurmountable and bring stabilized products
into clinical development as early as possible. We understand that every month lost
in development is a month of revenue lost post marketing authorization.
Arecor is seeking partners interested in the development of new or off-patent (or near patent expiry) biologics for whom they can develop advanced formulations with superior stability profiles. Examples of some partnered projects are listed below:
| Example | Route of Administration | Presentation | Objective |
|---|
| Biodefense vaccine | Subcutaneous or IM | Liquid | Significantly improved shelf life |
| Clotting factors | Infusion i.v. | Liquid | Stable aqueous preparation to replace powder for reconstitution |
| Follow-on biologic | Subcutaneous | Liquid | Patent extension with improved formulation |
| High conc mAbs | Subcutaneous | Liquid | Improved delivery |
| High conc. hormone | Subcutaneous | Liquid | More convenient presentation stable at room temperature |
| In-dwelling sensor | Subcutaneous | Dry | Terminal sterilization; stable at 37°C (body temperature) |
| Polysacchride vaccine | Subcutaneous | Liquid | Stable outside the cold chain at 37°C |
| Protein Depot | Subcutaneous | Dry | Terminal sterilization; depot stable at 37°C (body temperature) |
| Single Chain Antibody | Ophthalmic | Liquid | Stable at 2-8°C with <4% aggregation |
| Therapeutic enzyme | Infusion | Liquid | Stable aqueous preparation to replace powder for reconstitution |
| Topical Protein | Patch | Liquid | Stable at 37°C (body temperature) |
| Virus-like particle | Subcutaneous | Liquid | Stable outside the cold chain at 37°C |
To explore partnering opportunities contact us at
info@arecor.com or use the
Enquiry Form.